Borealis and Borouge, leading providers of innovative, value-creating plastics solutions, announce the introduction of Borealis Bormed™ BJ868MO, a high flow, heterophasic polypropylene copolymer used for the production of medical and diagnostic devices. This new and regulated solution is an important extension of the dedicated Borealis Bormed™ portfolio of polyethylene and polypropylene products. As part of the Bormed™ Concept service package encompassing Service, Commitment, and Conformance, Bormed BJ868MO reinforces the Borealis and Borouge commitment to healthcare industry customers. Validation of this newly-developed material solution was carried out in cooperation with Premix Oy, a leading manufacturer of electrically conductive and high frequency plastics. The official global launch of Bormed BJ868MO will take place on 6 February at Pharmapack 2019 in Paris, France.
Because we care: extending the Bormed portfolio with a regulated solution
A range of societal and technological developments is driving market demand for medical and diagnostic devices. Longer life expectancies and ageing populations have increased the importance of early diagnostics for disease prevention. Technological innovation is driving development of novel devices that are portable, smaller, and in some cases operated by patients themselves.
At the same time, regulation of medical and diagnostic devices is becoming more stringent, particularly in Europe. Two pertinent EU regulations include the Medical Device Regulation (MDR) and the In-Vitro Diagnostics Regulation (IVDR), both of which aim to improve patient safety by introducing stricter procedures for conformity assessment of such devices.
Borealis Bormed BJ868MO was developed for the express purpose of enabling Borealis and Borouge healthcare customers to achieve full regulatory compliance in the production of medical and diagnostic devices such as pipettes. Moreover, because Bormed BJ868MO is also part of the Bormed Concept, Borealis and Borouge customers can rely on a secure, long-term supply of materials in compliance with European, US Pharmacopeia, and ISO standards. The Bormed Concept also ensures long-term security of supply thanks to a two-year pre-notification period informing customers of any changes to the product. It also guarantees superior product quality and consistency, as well as long-term product traceability thanks to retention of Quality Control data and samples.
Collaboration produces new benchmark in in vitro diagnostics materials
The validation of the newly-developed Bormed BJ868MO is the result of intensive collaboration among Borealis, Premix Oy, and a leading medical diagnostics company.
Based in Finland, Premix Oy is a European market leader and global pioneer in the area of electrically conductive and high frequency plastics used in the healthcare and other industries. Since the early 1990s, proprietary PRE-ELEC© Premix compounds have been used in automated liquid handling applications. Because these electrically conductive plastic compounds enable extremely accurate liquid level detection, they are now widely used in in vitro diagnostics to ensure precise measurement. Premix compounds have set new material quality standards in the industry.
Borealis Bormed BJ868MO was utilized as a base for a new electrically conductive compound used in the production of high precision pipettes. In addition to being covered by the Bormed Concept, this new material solution offers several compelling benefits.
• High impact resistance minimizes risk of breakage for the end user;
• High impact resistance also ensures good drop performance of final device in varying conditions (at refrigerator, deep freezer and sub-zero temperatures);
• Superior high flow enables fast and easy mould filling; flow length-wall thickness ratios of up to 300 provide for very good dimensional stability;
• Lower holding pressures, lower processing temperatures and faster cycle times enhance sustainability thanks to reduced energy consumption and CO2 emissions.
“At Premix, our constant aim is to improve the safety of materials used in the healthcare industry, among others, in order to make society as a whole safer, too,” says Noora Kuusisto, Premix Oy Global Business Development Manager. “We are pleased that this constructive collaboration with Borealis has enabled us to establish together a new benchmark for quality standards in in vitro diagnostics materials.”
“It is our goal to Keep Discovering new solutions that help our customers and partners meet the challenges of today’s rapidly evolving healthcare market,” states Paulo Cavacas, Borealis Business Development Manager Healthcare. “We are pleased to have launched two important new additions to our Bormed portfolio Bormed BJ868MO and in October last year, the plastomer Bormed PL8830-PH which facilitate easier compliance with existing regulatory frameworks covering medical devices and pharmaceutical packaging.”
Borealis and Borouge are presenting their diverse Bormed™ portfolio of plastics solutions for pharmaceutical packaging, medical and diagnostic devices at Pharmapack 2019 and at the MD&M West.
From 6-8 February at Pharmapack 2019, booth H58 at the Paris Expo, Porte de Versailles, in Paris, France
From 5-7 February at the MD&M West, booth 3079 at the Anaheim Convention Center in Anaheim, California.
About Borealis Healthcare
As a leading supplier of innovative products and solutions for the healthcare industry, Borealis (borealisgroup.com | borealisbecausewecare.com) has been delivering value creation through innovation to its customers for over 30 years. Building on its portfolio of dedicated Bormed™ products and the three principles of the Bormed Concept Commitment, Service and Conformance Borealis offers advanced polyolefins for medical devices, pharmaceuticals and diagnostic packaging. Its solutions provide superior technical performance and fulfil the most specific and stringent requirements when it comes to safety and quality. Its long-term commitment to working with its customers to address tomorrow’s healthcare challenges makes it a reliable and trusted partner. As a global supplier, Borealis can ensure the security of supply and provide tailored technical support.
About Borealis and Borouge
Borealis is a leading provider of innovative solutions in the fields of polyolefins, base chemicals and fertilizers. With its head office in Vienna, Austria, the company currently has around 6,600 employees and operates in over 120 countries. Borealis generated EUR 7.5 billion in sales revenue and a net profit of EUR 1,095 million in 2017. Mubadala, through its holding company, owns 64% of the company, with the remaining 36% belonging to Austria-based OMV, an integrated, international oil and gas company. Borealis provides services and products to customers around the world in collaboration with Borouge, a joint venture with the Abu Dhabi National Oil Company (ADNOC).
Borealis and Borouge aim to proactively benefit society by taking on real societal challenges and offering real solutions. Both companies are committed to the principles of Responsible Care®, an initiative to improve safety performance within the chemical industry, and work to solve the world’s water and sanitation challenges through product innovation and their Water for the World programme.
Bormed is a trademark of Borealis AG